Toscano G et al., 2020; Guillain-Barré Syndrome Associated with SARS-CoV-2 (Letter to the editor); NEJM; April 27, 2020
DOI: 10.1056/NEJMc2009191
Delmont E et al., 2019; Relevance of anti-HNK-1 Antibodies in the management of anti-MAG neuropathies. J Neurol; published online 14 May, 2019; https://doi.org/10.1007/s00415-019-09367-0
DOI: 10.1007/s00415-019-09367-0
Choi K-D et al., 2019; Characteristics of a single oculomotor nerve palsy associated with anti-GQ1b antibody; J Neurol 266: 476–479
DOI: 10.1007/s00415-018-9161-8
Yoon L et al., 2019: Clinical characterization of anti—GQ1b antibody syndrome in Korean children.
J Neuroimmunology 15(330): 170-173
DOI: 10.1016/j.jneuroim.2019.01.003
Lee S U et al., 2019: Anti-ganglioside antibody associated acute unilateral vestibulopathy.
J Neurol 266(1): 250-252
DOI: 10.1007/s00415-018-9109-z
Sohn S Y and Kim J K, 2018: Neutropenia Following Intravenous Immunoglobulin Administration in a Patient with Multifocal Motor Neuropathy with Conduction Block.
J Neurol Neurophysiol 8:409. doi:10.4172/2155-9562.1000409
DOI: 10.4172/2155-9562.1000409
Franciotta D et al., 2018: Anti-ganglioside antibodies: experience from the Italian Association of Neuroimmmunology external quality assessment scheme.
Clin Chem Lab Med; 56 (11): 1921-1925
DOI: 10.1515/cclm-2018-0234
Legast G M et al., 2017: Guillain-Barré and Miller Fisher Overlap Syndrome Mimicking Alimentary Botulism. J Clin Neurol 13(4): 442-443
DOI: 10.3988/jcn.2017.13.4.442
Han T H et al., 2017: Transient Lower Bulbar Palsy with Elevated Serum anti-GM1 and Anti-GD1b Antibodies during Aripiprazole Treatment. Pediatr Neurol 66: 96-99.
DOI: 10.1016/j.pediatrneurol.2016.07.011
Herrendorff R et al., 2017: Selective in vivo removal of pathogenic anti-MAG autoantibodies, an antigen specific treatment option for anti-MAG neuropathy. PNAS,
www.pnas.org/cgi/doi/10.1073/pnas.1619386114
DOI: 10.1073/pnas.1619386114
Anaya J-M et al., 2017: A comprehensive analysis and immunobiology of autoimmune neurological syndromes during the Zika virus outbreak in Cúcuta, Colombia. Journal of Autoimmunity 77: 123-138
DOI: 10.1016/j.jaut.2016.12.007
Spatola M et al., 2016: Serum and CSF GQ1b antibodies in isolated ophthalmologic syndromes.
Neurology 86: 1780-1784
DOI: 10.1212/WNL.0000000000002558
Cao-Lormeau V M et al., 2016: Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 387 (10027); 1531-1539
(incl. supplement).
DOI: 10.1016/S0140-6736(16)00562-6
BÜHLMANN GanglioCombi at the forefront of newly emerging post-infectious forms of Guillain-Barré syndromes such as those associated with Zika viruses.
Kollewe K et al., 2015: Anti-Ganglioside Antibodies in Amyotrophic Lateral Sclerosis Revisited.
PLoS One, 10(4): e0125339.
DOI: 10.1371/journal.pone.0125339
BÜHLMANN GanglioCombi at the utmost importance of daily questions such as the differentiation between Multifocal Motor Neuropathies (MMN, treatable) and MMN- mimicking disorders such as Amyotrophic Lateral Sclerosis (ALS, not treatable). This is the biggest ALS cohort investigated to date and demonstrates that frequency of anti-Ganglioside antibodies is not different from apparently healthy normal blood donors.
Delmont E et al., 2017: Value of anti-HNK-1 Antibodies in anti-MAG Neuropathies: an analysis of 144 sera. Poster presented at 2017 “Peripheral Nerve Society” (PNS) Annual Meeting in Sitges (ES)
Anti-MAG Antibodies have good sensitivity and specificity to detect anti-MAG Neuropathy. Notably, titres of anti-HNK-1 antibodies are related to the disease activity.
Chalah M A et al., 2016: A comparison of four commercial tests for detecting anti-ganglioside antibodies in patients with well-characterized dysimmune peripheral neuropathies.
Poster presented at “International Congress on Autoimmunity”, Leipzig (GE).
BÜHLMANN GanglioCombi(R) ELISA compared to competitor Assays has best performance and qualifies for Assay of choice for daily clinical routine application.
Mani B et al., 2010: The Frequency of anti-Ganglioside Antibodies in Blood Donors Compared to Control Groups and Guillain-Barré Syndrome Patients. Poster presented at “10th Dresden Symposium on Autoantibodies”, Dresden (GE).
Wurster U et al., 2009: Ganglioside Antibodies in Amyotrophic Lateral Sclerosis. Poster presented at “9th Dresden Symposium on Autoantibodies”, Dresden (GE).
Kenina V et al., 2015: Clinical Impact and Relevance of Antiganglioside Antibodies Test Results.
Proc. Latvian Acad. Sci., Section B, 69(5): 223-227
Uysalol M et al., 2013: A Rare Form of Guillain-Barré Syndrome: A Child Diagnosed with Anti-GD1a and Anti-GD1b Positive Pharyngeal-Cervical-Brachial Variant. Balkan Med J; 30:337-341
DOI: 10.5152/balkanmedj.2013.8334
Lei T et al., 2012: Anti-ganglioside antibodies were not detected in human subjects infected with or vaccinated against 2009 pandemic influenza A (H1N1) virus. Vaccine 30: 2605-2610
DOI: 10.1016/j.vaccine.2012.02.009
Sharma M B et al., 2011: The presence of Mycoplasma pneumoniae infection and GM1 ganglioside antibodies in Guillain-Barré syndrome. J Infect Dev Countries 5(6): 459-464
DOI: 10.3855/jidc.1508
